BZYR Stock Overview
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to the treatment of various cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Burzynski Research Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.024 |
| 52 Week High | US$0.086 |
| 52 Week Low | US$0.013 |
| Beta | 1.48 |
| 1 Month Change | 51.88% |
| 3 Month Change | -53.31% |
| 1 Year Change | -32.50% |
| 3 Year Change | -51.30% |
| 5 Year Change | 51.88% |
| Change since IPO | -19.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| BZYR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -3.7% |
| 1Y | -32.5% | -2.0% | 20.5% |
Return vs Industry: BZYR underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: BZYR underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| BZYR volatility | |
|---|---|
| BZYR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BZYR's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BZYR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Stanislaw Burzynski | burzynskiresearch.com |
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to the treatment of various cancers. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services.
Burzynski Research Institute, Inc. Fundamentals Summary
| BZYR fundamental statistics | |
|---|---|
| Market cap | US$3.19m |
| Earnings (TTM) | -US$1.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs BZYR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BZYR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.19m |
| Earnings | -US$1.19m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.009 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BZYR perform over the long term?
See historical performance and comparison